Ryan De Vries

IP Intensive: A Semester at TEVA Canada

This past fall, I had an opportunity to work with the patent strategy group at Teva Canada as part of Osgoode’s Intellectual Property Law Intensive Program. Teva Canada is the Canadian branch of Teva Pharmaceutical Industries Ltd., a company commonly known as one of the largest generic pharmaceutical companies in the world, though it also […]

What Should Be Included in a Canadian Orphan Drug Regulatory Framework

As the new Liberal government turns its mind to the application of substantive policies, it will have to decide what to do with the Canadian orphan drug regulatory framework (ODRF) that has been in development. This framework, based in large part on the example of the United States Orphan Drug Act (US ODA), which has […]